Dokumentuaren aipamena

APA (7th ed.) Zitazioa
Erika, M., Challayne, K., L, S. J., Steven, M., Martin, K., Steve, K., . . . AJ, A. S. (2007). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC.
Chicago Style (17th ed.) Zitazioa
Erika, Mehl, et al. Kisspeptin and GPR54 Immunoreactivity in a Cohort of 518 Patients Defines Favourable Prognosis and Clear Cell Subtype in Ovarian Carcinoma. BMC, 2007.
MLA (9th ed.) Zitazioa
Erika, Mehl, et al. Kisspeptin and GPR54 Immunoreactivity in a Cohort of 518 Patients Defines Favourable Prognosis and Clear Cell Subtype in Ovarian Carcinoma. BMC, 2007.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.